Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models

Journal:
Cancer Cell
Published:
Affiliations:
10
Authors:
22
Institutions Authors Share
IFOM - FIRC Institute of Molecular Oncology, Italy
6.833333
0.31
University of Turin (UNITO), Italy
6.500000
0.30
Candiolo Cancer Institute (FPO-IRCCS), Italy
2.500000
0.11
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
2.000000
0.09
San Raffaele Scientific Institute, Italy
1.500000
0.07
Cogentech S.c.a.r.l., Italy
1.333333
0.06
University of Milan (UNIMI), Italy
0.833333
0.04
Vita-Salute San Raffaele University (UniSR), Italy
0.500000
0.02